spacer

Innovations in Pharmaceutical Technology
Innovations in Pharmaceutical Technology
IPT was launched in 1997 to provide the pharmaceutical industry with quality information on the latest cutting-edge technologies.
 
International Clinical Trials
International Clinical Trials
ICT is a specialist journal designed to provide global coverage of key topics pertinent to the clinical trials sector.
 
Pharmaceutical Manufacturing and Packing Sourcer
Pharmaceutical Manufacturing and Packing Sourcer
PMPS is a specialist journal designed to provide worldwide coverage of a range of topics relating to the pharmaceutical manufacturing and packaging sector.
 
European Biopharmaceutical Review
European Biopharmaceutical Review
EBR is well-recognised for providing beneficial information to players in the bio-industry including entrepreneurial biopharmaceutical and life science companies
 

 

 

Website design and development by Rubler Studio
spacer

Member login

E-mail address:

Password:
Remember me

.
News and Press Releases

Merck Announces Collaboration with Agilent Technologies to Fill Industry Gap in Process Analytical Technologies for Downstream Processing

Darmstadt, Germany, June 14, 2022: Merck, a leading science and technology company, today announced that it has entered a collaboration with Agilent Technologies to advance Process Analytical Technologies (PAT). PAT, which is strongly encouraged by global regulatory authorities, is a key enabler for real-time release and Bioprocessing 4.0.
More info >>

.
White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement